• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Financial Services·LWEL
Share

Luckwel Pharmaceuticals Inc. Stocks

$ 0Last Updated 23.03.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Luckwel Pharmaceuticals Inc. does not have significant operations. It focuses to acquire, develop, manufacture, and market pharmaceutical medications. The company was formerly known as Luckycom Pharmaceuticals Inc. and changed its name to Luckwel Pharmaceuticals Inc. in April 2018. Luckwel Pharmaceuticals Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is underpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

05.08.2026 11:43

Following Musk's Example: Revolut's CEO Could Receive Europe's Largest Bonus Package

05.08.2026 11:09

AI agents from OpenAI and Anthropic went out of control and attacked real-world targets 19 times

05.08.2026 10:37

Top Stories This Morning: AI Cyber Risks at OpenAI and Anthropic, SpaceX's Report, and Burry Goes Against the Market

05.08.2026 10:06

A Trillion by 2030 and Moon Factories: Musk’s Key Statements Following the SpaceX Report

05.08.2026 09:30

An analyst recommended reducing the proportion of Apple shares in the portfolio due to rising memory prices

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026